The director of Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, associate professor of neurology, Albert Einstein College of Medicine, discussed recent developments in Alzheimer disease research, including FDA approval of aducanumab, as well as the importance of engaging community-based organizations to improve patient care.
The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease commented on social determinants of health in relation to telemedicine and community willingness to engage.
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center discussed the adjustments clinicians and patients with sleep disorders made throughout the pandemic, including the increased use of telemedicine.
In Alzheimer disease and dementia, Jessica Zwerling, MD, MS, director, Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, believes normalizing trial recruitment aids and telehealth to increase participation is another way to ease delivery of care.
Challenges surrounding the use of telehealth for patients with Alzheimer disease are affected by technological barriers, according to the associate director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease
The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease discusses the use of telehealth for patients with Alzheimer disease during the COVID-19 pandemic, as well as her thoughts on why it is here to stay.
Jessica Zwerling, MD, associate director, Center for the Aging Brain, Montefiore Medical Center, discussed the impact that telemedicine has had in Alzheimer and dementia care.
The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Michael J. Thorpy, MD.
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.
The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.
The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.
A post-hoc analysis of the phase 2/3 trial of rimegepant revealed early and sustained efficacy compared to placebo, with significant reductions in weekly migraine days.
The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.
Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.
The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.
Solomon L Moshe, MD, and Elissa Yozawitz, MD, from Montefiore Medical Center, discussed ways of reducing misdiagnosis of neonatal seizures and the future work needed to be done in this space.
The duo from Montefiore Medical Center detailed the reasons why EEGs must remain an interictal part in improving rates of misdiagnosing neonatal seizures.
The duo from Montefiore Medical Center discussed a variety of topics surrounding an effort to improve seizure diagnosis and classification in newborns.
With the COVID era changing social environments and interactions, making sure patients can maintain social connections is as important as ever.
The duo from Montefiore Medical Center discussed how the advancement of technology has benefitted diagnosing epilepsy and classifying seizures in newborns.
The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.
The duo from Montefiore Medical Center discussed new modifications to the 2017 International League Against Epilepsy (ILAE) classification of seizures and epilepsies, relevant to neonates.
A recent study investigated self-reported outcomes of preventive treatment prior to the introduction of calcitonin gene related peptide (CGRP) receptor targeting.
The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.
The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.
The director of the Montefiore Headache Center discussed how rimegepant was observed to produce clinically meaningful improvements in migraine prevention.
The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.
The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.
The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.
